Read Research Alzheimer's More' title='Share this by email.' class='social email'>           

Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial

Alzheimer’s disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer’s disease (S-CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in patients with AD. Read & Research Alzheimer’s More

Leave a Reply